These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effect of transdermal 17 beta-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause. Reginster JY; Christiansen C; Dequinze B; Deroisy R; Gaspard U; Taquet AN; Franchimont P Calcif Tissue Int; 1993 Jul; 53(1):13-6. PubMed ID: 8394191 [TBL] [Abstract][Full Text] [Related]
23. Clinical and metabolic responses of menopausal women to sequential versus continuous estrogen and progestin replacement therapy. Luciano AA; Turksoy RN; Carleo J; Hendrix JW Obstet Gynecol; 1988 Jan; 71(1):39-43. PubMed ID: 2827082 [TBL] [Abstract][Full Text] [Related]
24. Do estrogens improve bone mass in osteoporotic women over ten years of menopause. Szejnfeld VL; Souen JS; Baracat EC; Atra E; de Lima GR Sao Paulo Med J; 1994; 112(1):517-21. PubMed ID: 7871318 [TBL] [Abstract][Full Text] [Related]
25. Continuous combined piperazine oestrone sulphate and medroxyprogesterone acetate hormone replacement therapy--a study of bleeding pattern, endometrial response, serum lipid and bone density changes. Nand SL; Webster MA; Wren BG Aust N Z J Obstet Gynaecol; 1995 Feb; 35(1):92-6. PubMed ID: 7772012 [TBL] [Abstract][Full Text] [Related]
26. [Absence of antiosteopenic effect of hormone replacement therapy in postmenopausal women]. Ortiz Núñez DA; Mengchún López G; Hernández Marín I; Mendoza R; Ayala Ruíz AR Ginecol Obstet Mex; 2004 Jul; 72():349-55. PubMed ID: 15469174 [TBL] [Abstract][Full Text] [Related]
27. Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women. Grey A; Cundy T; Evans M; Reid I Clin Endocrinol (Oxf); 1996 Mar; 44(3):293-6. PubMed ID: 8729524 [TBL] [Abstract][Full Text] [Related]
28. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women. Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM Menopause; 2008; 15(2):357-62. PubMed ID: 17925661 [TBL] [Abstract][Full Text] [Related]
29. Sequential use of conjugated estrogens and medroxyprogesterone in the climacteric syndrome: clinical and histological findings. Figueroa-Casas PR; Schlaen I Maturitas; 1988 Mar; 9(4):309-13. PubMed ID: 2837619 [TBL] [Abstract][Full Text] [Related]
30. A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy. Adachi JD; Sargeant EJ; Sagle MA; Lamont D; Fawcett PD; Bensen WG; McQueen M; Nazir DJ; Goldsmith CH Br J Obstet Gynaecol; 1997 Jan; 104(1):64-70. PubMed ID: 8988699 [TBL] [Abstract][Full Text] [Related]
31. Effect of continuous and sequential oral estrogen-progestogen replacement regimens on postmenopausal bone loss: a 2-year prospective study. Figueras F; Castelo-Branco C; Pons F; Sanjuán A; Vanrell JA Eur J Obstet Gynecol Reprod Biol; 2001 Dec; 99(2):261-5. PubMed ID: 11788184 [TBL] [Abstract][Full Text] [Related]
32. A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Meschia M; Brincat M; Barbacini P; Crossignani PG; Albisetti W Calcif Tissue Int; 1993 Jul; 53(1):17-20. PubMed ID: 8394192 [TBL] [Abstract][Full Text] [Related]
33. Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy. Cosman F; Nieves J; Shen V; Lindsay R J Bone Miner Res; 1995 Apr; 10(4):594-600. PubMed ID: 7610930 [TBL] [Abstract][Full Text] [Related]
34. Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women. Gibbons WE; Moyer DL; Lobo RA; Roy S; Mishell DR Am J Obstet Gynecol; 1986 Feb; 154(2):456-61. PubMed ID: 3004222 [TBL] [Abstract][Full Text] [Related]
35. [Effect of low-dose or standard-dose conjugated equine estrogen combined with different progesterone on bone density in menopause syndrome women]. Zuo HL; Deng Y; Wang YF; Gao LL; Xue W; Zhu SY; Ma X; Sun AJ Zhonghua Fu Chan Ke Za Zhi; 2018 Apr; 53(4):243-247. PubMed ID: 29747269 [No Abstract] [Full Text] [Related]
36. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. Prior JC; Vigna YM; Wark JD; Eyre DR; Lentle BC; Li DK; Ebeling PR; Atley L J Bone Miner Res; 1997 Nov; 12(11):1851-63. PubMed ID: 9383690 [TBL] [Abstract][Full Text] [Related]
37. Prevention of osteoporosis by medroxyprogesterone acetate in postmenopausal women. McNeeley SG; Schinfeld JS; Stovall TG; Ling FW; Buxton BH Int J Gynaecol Obstet; 1991 Mar; 34(3):253-6. PubMed ID: 1673944 [TBL] [Abstract][Full Text] [Related]
38. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women. Osmanağaoğlu MA; Osmanağaoğlu S; Osmanağaoğlu T; Okumuş B; Bozkaya H Fertil Steril; 2005 Aug; 84(2):384-93. PubMed ID: 16084879 [TBL] [Abstract][Full Text] [Related]
39. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Cundy T; Cornish J; Roberts H; Reid IR Am J Obstet Gynecol; 2002 May; 186(5):978-83. PubMed ID: 12015524 [TBL] [Abstract][Full Text] [Related]
40. Effects of 2 years of hormone replacement upon bone mass, serum lipids and lipoproteins. Webber CE; Blake JM; Chambers LF; Roberts JG Maturitas; 1994 May; 19(1):13-23. PubMed ID: 7935028 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]